Why Incyte ( INCY ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Incyte ( INCY ) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cellebrite ( CLBT ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, November 12, 2025 at 5:00 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Peering Into Incyte Corp's Recent Short Interest - Incyte ( NASDAQ:INCY )
Incyte Corp's ( NYSE:INCY ) short interest as a percent of float has risen 10.08% since its last report. According to exchange reported data, there are now 9.36 million shares sold short, which is 6.77% of all regular shares that are available for trading.
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of ...
Knight Therapeutics Reports Third Quarter 2025 Results
Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception Increased 2025 financial guidance ...
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates - ALPS Group ( NASDAQ:ALPS ) , Denny's ( NASDAQ:DENN )
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.91% to 46,906.05 while the NASDAQ dipped 1.59% to 23,456.33. The S&P 500 also fell, dropping, 1.17% to 6,772.04.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs ...
Prelude Therapeutics Announces Strategic Business Update - Prelude Therapeutics ( NASDAQ:PRLD )
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program ...
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - Incyte ( NASDAQ:INCY ) , Prelude Therapeutics ( NASDAQ:PRLD )
Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms ( MPNs )
Knight Therapeutics Announces Approval and Launch of MINJUVI® ( tafasitamab ) in Argentina
MONTREAL, Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory approval and has launched MINJUVI® in ...
Insider trading is an SEC country club looking for a scapegoat
Crypto's transparency reveals market manipulation that traditional finance hides. Century-old laws riddled with loopholes enable unpunished manipulation.
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms - Incyte ( NASDAQ:INCY )
Incyte Corporation's ( NASDAQ:INCY ) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion. Total revenues increased 20% year over year, primarily driven by a rise in total net product revenues. Total net product revenue was $1.15 billion, representing a ...
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
Incyte ( INCY ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Tuesday, Oct. 28, 2025, at 8 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Incyte ( INCY ) Tops Q3 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
Syndax Announces FDA Approval of Revuforj® ( revumenib ) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Syndax Pharmaceuticals ( NASDAQ:SNDX )
- First and only therapy FDA approved in both R/R acute myeloid leukemia ( AML ) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation - - Second approved indication for Revuforj in less than one year further solidifies Syndax's leadership in menin inhibition -
Eli Lilly's New Ebglyss Results Back Flexible Treatment Options For Atopic Dermatitis - Eli Lilly ( NYSE:LLY )
Eli Lilly and Co. ( NYSE:LLY ) on Friday shared new results from Ebglyss ( lebrikizumab-lbkz ) for moderate-to-severe atopic dermatitis. Ebglyss showed sustained similar levels of skin clearance when administered as a single injection of 250 mg once every eight weeks ( Q8W ) compared with ...
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
GSK ( GSK ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market - Innovent Biologics ( OTC:IVBIY ) , Takeda Pharmaceutical Co ( NYSE:TAK )
The collaboration combines Innovent's proven immuno-oncology ( "IO" ) and antibody-drug conjugate ( "ADC" ) R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an ...
Incyte ( INCY ) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You Looking for a Top Momentum Pick? Why Incyte ( INCY ) is a Great Choice
Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Positive Regulatory Updates Further Boost INCY Stock?
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
INCY or ARGX: Which Is the Better Value Stock Right Now?
INCY vs. ARGX: Which Stock Is the Better Value Option?
Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock?
LH is poised for Q3 growth, with revenue and EPS estimates pointing higher as diagnostics and biopharma units deliver strong performances.
Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Incyte's ( INCY ) EVP and General Counsel Sold 4,100 Shares for $352,000
On October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte ( NASDAQ:INCY ) , executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this SEC Form 4 filing.Transaction value calculated using the SEC Form 4 weighted average purchase ...
Abbott to Report Q3 Earnings: Medical Devices Arm in Focus
ABT's Q3 results may show strength in Medical Devices and Nutrition, offsetting softness in Diagnostics.
Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell?
Tempus AI sharpens its edge in precision medicine with key acquisitions, strong R&D launches, and improving financials amid rising competition.
TLRY Gears Up to Report Q1 Earnings: Cannabis Recovery in Focus
Tilray Brands' fiscal first-quarter report is likely to highlight international cannabis gains, European expansion and wellness growth.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Will Incyte ( INCY ) Beat Estimates Again in Its Next Earnings Report?
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - Maze Therapeutics ( NASDAQ:MAZE )
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Maze Therapeutics, Inc. ( NASDAQ:MAZE ) , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot ...
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Maze Therapeutics, Inc. ( Nasdaq: MAZE ) , a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot ...
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
INCY vs. ARGX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte ( INCY Quick QuoteINCY - ) and argenex SE ( ARGX Quick QuoteARGX - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
China Medical System ( 867.HK; 8A8.SG ) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
China Medical System (867.HK. 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication ...
China Medical System ( 867.HK; 8A8.SG ) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication
SHENZHEN, CHINA, Sept. 28, 2025 ( GLOBE NEWSWIRE ) -- China Medical System Holdings Limited ( "CMS" ) is pleased to announce that its subsidiaries, Dermavon Holdings Limited ( "Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on ...
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
MONTREAL, Sept. 26, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. ( TSX:GUD ) ( "Knight" or "the Company" ) is pleased to announce it has ranked No. 384 on the 2025 Report on Business magazine's ranking of Canada's Top Growing Companies.
Strength Seen in Oculis Holding AG ( OCS ) : Can Its 6.7% Jump Turn into More Strength?
Oculis Holding AG (OCS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jim Cramer Spotlights These Undervalued S&P 500 Stocks With Growth Potential Amid Skyrocketing Market - Apollo Asset Management ( NYSE:APO ) , American Express ( NYSE:AXP )
In a recent episode of "Mad Money," Jim Cramer identified several stocks in the S&P 500 that he believes are undervalued, offering growth potential despite the market's record highs. Cramer, the host of CNBC's "Mad Money," highlighted a range of stocks from different sectors that he believes are ...
Jim Cramer names inexpensive stocks worth buying as the S&P 500 heads higher
Jim Cramer says there are still bargains in the S&P 500, highlighting names like T-Mobile, Dollar Tree, Caterpillar and Dell as growth at value.
